Comparison of Trial-Collected and Parent-Reported Race and Ethnicity in a Children’s Oncology Group Trial

Publication Citation

Fry C, Robinson E, Weller E, Paul MA, Aziz-Bose R, Duhaney L, Griffin M, Karvonen K, Kelly CA, Kang S, Newman H, Umaretiya PJ, Zheng DJ, Gupta S, Rau RE, Teachey DT, Alexander S, Kairalla JA, Bona K. Comparison of Trial-Collected and Parent-Reported Race and Ethnicity in a Children’s Oncology Group Trial. JAMA Netw Open. 2026 Nov 2;9(11):e2643427. doi: 10.1001/jamanetworkopen.2026.43427. PMID: 43013311; PMCID: PMC13756129.

Abstract

Children with cancer who are Black or Hispanic are more likely to experience cancer recurrence and die, despite standardized treatment on National Clinical Trials Network (NCTN) Children’s Oncology Group (COG) trials.1 Accurate race and ethnicity data are essential to characterizing these disparities and designing effective interventions. Race and ethnicity are social—not biological—constructs, and self-identification is the accepted standard for clinical trials in the US.2 Although journals request “an explanation of who identified participant race and ethnicity and the source of classifications,”3 these data are frequently unavailable.4 In practice, COG case report forms (CRFs) do not document who identified participant race or ethnicity. While studies in general pediatrics have demonstrated discordance between electronic health record–documented and parent-reported race and ethnicity,5,6 to our knowledge, no studies have examined analogous misclassification in pediatric clinical trials—an important gap with potential implications for interpreting trial outcomes. We aimed to evaluate missingness and concordance between trial-collected and parent-reported race and ethnicity data from a COG trial for newly diagnosed pediatric acute lymphoblastic leukemia (ALL).

Link To Publication